Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone
Authors:
- Andrew A NierenbergANAndrew A Nierenberg
- Michael J OstacherMOMichael J Ostacher
- Joseph R CalabreseJCJoseph R Calabrese
- Terence A KetterTKTerence A Ketter
- Lauren B MarangellLMLauren B Marangell
- David J MiklowitzDMDavid J Miklowitz
- Sachiko MiyaharaSMSachiko Miyahara
- Mark S BauerMBMark S Bauer
- Michael E ThaseMTMichael E Thase
- Stephen R WisniewskiSWStephen R Wisniewski
- Gary S SachsGSGary S Sachs
- 1 February 2006
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 163 (2) , 210-216
Abstract
OBJECTIVE: Clinicians have few evidence-based options for the management of treatment-resistant bipolar depression. This study represents the first randomized trial of competing options for treatment-resistant bipolar depression and assesses the effectiveness and safety of antidepressant augmentation with lamotrigine, inositol, and risperidone. METHOD: Participants (N=66) were patients with bipolar I or bipolar II disorder enrolled in the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). All patients were in a current major depressive episode that was nonresponsive to a combination of adequate doses of established mood stabilizers plus at least one antidepressant. Patients were randomly assigned to open-label adjunctive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks. The primary outcome measure was the rate of recovery, defined as no more than two symptoms meeting DSM-IV threshold criteria for a mood episode and no significant symptoms present for 8 weeks. RESULTS: No significant between-group differences were seen when any pair of treatments were compared on the primary outcome measure. However, the recovery rate with lamotrigine was 23.8%, whereas the recovery rates with inositol and risperidone were 17.4% and 4.6%, respectively. Patients receiving lamotrigine had lower depression ratings and Clinical Global Impression severity scores as well as greater Global Assessment of Functioning scores compared with those receiving inositol and risperidone. CONCLUSIONS: No differences were found in primary pairwise comparison analyses of open-label augmentation with lamotrigine, inositol, or risperidone. Post hoc secondary analyses suggest that lamotrigine may be superior to inositol and risperidone in improving treatment-resistant bipolar depression.Keywords
This publication has 35 references indexed in Scilit:
- An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depressionBiological Psychiatry, 2005
- Pramipexole for bipolar II depression: a placebo-controlled proof of concept studyBiological Psychiatry, 2004
- Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I DepressionArchives of General Psychiatry, 2003
- Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)Biological Psychiatry, 2003
- A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Manic or Hypomanic Patients With Bipolar I DisorderArchives of General Psychiatry, 2003
- A Prospective Investigation of the Natural History of the Long-term Weekly Symptomatic Status of Bipolar II DisorderArchives of General Psychiatry, 2003
- The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I DisorderArchives of General Psychiatry, 2002
- Flexible treatment strategies in chronic disease: clinical and research implicationsBiological Psychiatry, 2000
- An efficacy study of electroconvulsive therapy and antidepressants in the treatment of primary depressionPsychological Medicine, 1982
- Lithium Carbonate and Imipramine in Prevention of Affective EpisodesArchives of General Psychiatry, 1973